Physician profile
Eric A Smith
NPI 1972533214
$2,903.16
in general payments reported to CMS, 2019-2025
38 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $315 · 2021: $310 · 2022: $460 · 2023: $590 · 2024: $402 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.79 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $275.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.78 | 2019-2025 | Jardiance, Jascayd |
| Amgen INC. | $132.02 | 2020-2024 | Evenity, Prolia |
| Organon LLC | $126.22 | 2022 | |
| Amarin Pharma, INC. | $106.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $100.06 | 2019-2023 | |
| Novo Nordisk INC | $96.59 | 2020-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $81.38 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astellas Pharma US INC | $65.84 | 2022-2025 | Veozah |
| Lilly USA, LLC | $65.42 | 2019-2023 | Emgality, Jardiance |
| Phathom Pharmaceuticals, INC. | $64.24 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $54.28 | 2023-2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $51.50 | 2021-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $45.19 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.